Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07GMF
|
|||
| Former ID |
DIB015183
|
|||
| Drug Name |
MVA-85A
|
|||
| Synonyms |
AERAS-485; MVA-AG85A; MVA-85A vaccine (Mycobacterium tuberculosis infection), Oxford-Emergent Tuberculosis Consortium/TB-VAC; MVA-Ag85A vaccine (Mycobacterium tuberculosis infection), Oxford-Emergent Tuberculosis Consortium/TB-VAC
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Mycobacterium infection [ICD-11: 1B10-1B21] | Phase 2 | [1] | |
| Company |
University of Oxford
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mycobacterium Antigen complex 85A (MycB fbpA) | Target Info | . | [2] |
| KEGG Pathway | Glycerolipid metabolism | |||
| Metabolic pathways | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01650389) Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination. U.S. National Institutes of Health. | |||
| REF 2 | MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults. Curr Opin Mol Ther. 2010 Feb;12(1):124-34. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.